Summary of included studies
Reference | Study design/participants | Intervention | ETCO2 criteria | Outcomes | Results | Quality assessment* |
---|---|---|---|---|---|---|
Burton et al 29 | Prospective observational 58 adults (only adults ≥18 years old included in analysis, median age: 38 years old) | Propofol, etomidate, midazolam, ketamine (doses not defined) Supplementary oxygen: 2 L/min (all patients) Monitoring: pulse oximetry, heart rate, cardiac rhythm, RR and interval BP, ETCO2 continuously | ETCO2 change of ≥10 mm Hg from presedation baseline or intrasedation ETCO2 ≤30 mm Hg or ≥50 mm Hg |
| Diagnostic OR: 4.83† 14/19 experienced changes in ETCO2 before hypoxia | 18 (low quality); moderate risk of bias |
Deitch et al 27 | RCT 110 adults (≥18 years old; median age: 37 years old) | 1–1.5 mg/kg intravenous propofol with additional 0.5 mg/kg boluses Procedure: abscess drainage (n=69); fracture/joint reduction (n=35) Supplementary oxygen: 3 L/min (56/110 patients) Monitoring: pulse oximetry, pulse rate, BP, ETCO2 continuously | ETCO2 ≥50 mm Hg, or ≥10% increase or decrease from baseline or loss of waveform |
| Diagnostic OR: 1.21 9/25 experienced changes in ETCO2 before hypoxia; 27/52 RD detected by ETCO2 only; 1/27 physicians identified RD according to ETCO2 | 25 (high quality); Low risk of bias |
Deitch et al 25 | RCT 132 adults (≥18 years old; median age: 34 years old) | 0.05 mg/kg morphine or 0.5 μg/kg fentanyl intravenously and then 1 mg/kg propofol with 0.5 mg/kg boluses Procedure: abscess drainage; fracture/joint reduction Supplementary oxygen: 3 L/min (all patients) Monitoring: pulse oximetry, pulse rate, BP, ETCO2 every 5 s | ETCO2 ≥50 mm Hg, or ≥10% increase or decrease from baseline or loss of waveform ≥15 s |
| Diagnostic OR: 154.72 Hypoxia: 17/68 (capnography) vs 27/64 (blinded capnography) 44/44 changes in ETCO2 before hypoxia; 32/76 RD detected by ETCO2 only; 5/38 interventions based on ETCO2 | 28 (high quality); low risk of bias |
Deitch et al 28 | Prospective observational 117 adults (≥18 years old, mean age: 34.5 years old) | 1 mg/kg propofol with additional 0.5 mg/kg boluses until desired level of sedation was achieved Supplementary oxygen: 15 L/min (in 59/117) Monitoring: pulse oximetry, pulse rate, BP, ETCO2 every 5 s | ETCO2 ≥50 mm Hg or ≥10% increase or decrease from baseline or loss of waveform ≥15 s |
| Diagnostic OR: 9.32 28/58 experienced RD identified by ETCO2 but did not develop hypoxia; 35/58 experienced hypoxia after RD; 29/35 experienced changes in ETCO2 before hypoxia; 16/31 interventions based on ETCO2 | 24 (moderate quality); high risk of bias |
Miner et al 26 | Prospective observational 74 adults (≥18 years old, mean age: 37.6 years old) | Methohexital/propofol/etomidate or fentanyl and midazolam (doses not defined) Supplementary oxygen: not given routinely (47/74 as part of airway management; concentration not stated) Monitoring: pulse oximetry, heart rate, BP, RR, ETCO2 every 2 min (+ modified version of the OAA/S scale) | ETCO2 >50 mm Hg or absent ETCO2 waveform or ETCO2 change from baseline >10 mm Hg |
| Diagnostic OR: 7.31 33/74 experienced RD 33/33 detected by ETCO2, 11/33 detected by pulse oximetry; 9/11 interventions based on ETCO2 | 24 (moderate quality); low risk of bias |
Miner et al 30 | Prospective observational 108 adults (≥18 years old, mean age: 40.9 years old) | Methohexital/propofol/etomidate or fentanyl and midazolam (doses not given) Supplementary oxygen: 87/108 (as part of airway management; dose not stated) Monitoring: pulse oximetry, heart rate, BP, ETCO2 continuously (+ EEG to calculate BIS score) | ETCO2 change from baseline >10 mm Hg or absent ETCO2 waveform |
| Diagnostic OR: 3.99 44/108 experienced RD 41/44 detected by ETCO2, 14/44 detected by pulse oximetry | 26 (high quality); low risk of bias |
Sivilotti et al 6 | RCT 63 adults (≥18 years old, mean age: 39 years old) | 0.3 mg/kg ketamine or 1.5 μg/kg fentanyl intravenously, 0.4 mg/kg propofol intravenously 2 min later and then 0.1 mg/kg boluses every 30 s Supplementary oxygen: if patients developed oxygen desaturation (number of patients and dose not stated) Monitoring: continuous pulse oximetry, ECG and BP, ETCO2 | ETCO2 >50 mm Hg or a rise or fall of >10 mm Hg from presedation baseline or loss of waveform for >30 s or recurrent losses of waveform |
| Diagnostic OR: 7.56 21/36 developed hypoxia and had ETCO2 changes but only 2/36 experienced changes in ETCO2 before hypoxia | 18 (low quality); moderate risk of bias |
*Quality assessment includes the Downs and Black Study Quality Score and the risk of bias according to the Cochrane Risk of Bias tool.13 ,15
†Diagnostic OR: the diagnostic accuracy of capnography to detect an adverse event was calculated as an OR for each study.
RD, respiratory depression.